3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine
C18H17N7O2S — CID 123917443
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine
3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine (PubChem CID 123917443) has the molecular formula C18H17N7O2S and a molecular weight of 395.45 g/mol. Its IUPAC name is 3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine.
Molecular Properties
| Compound Name | 3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine |
|---|---|
| PubChem CID | 123917443 |
| Molecular Formula | C18H17N7O2S |
| Molecular Weight | 395.45 g/mol |
| Exact Mass | 395.12 |
| IUPAC Name | 3-[6-(1-methyliminobut-2-en-2-yl)pyrazolo[4,5-b]pyridin-1-yl]sulfonylimidazo[1,2-a]pyridin-6-amine |
| SMILES | CC=C(/C=N/C)c1cnc2cnn(S(=O)(=O)c3cnc4ccc(N)cn34)c2c1 |
| InChI | InChI=1S/C18H17N7O2S/c1-3-12(7-20-2)13-6-16-15(21-8-13)9-23-25(16)28(26,27)18-10-22-17-5-4-14(19)11-24(17)18/h3-11H,19H2,1-2H3/b12-3?,20-7+ |
| InChIKey | JHPYMMGCZJDJGL-YIGFIDTISA-N |
| XLogP | 2.00 |
| TPSA | 120.53 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 395.45 |
| LogP ≤ 5 | 2.00 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'imine_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 123917443 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.